Work

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.211.211

Authors: Harry P. Erba, Moshe Y Levy, Sumithira Vasu, Anthony S. Stein, Amir T. Fathi, Michael B. Maris, Anjali Advani, Stefan Faderl, Scott E. Smith, Brent L. Wood, Roland B. Walter, Jay Yang, William B. Donnellan, Eric J. Feldman, Jenna L Voellinger, Farhad Ravandi

Institutions: University of Alabama at Birmingham, Baylor University Medical Center, The Ohio State University, City Of Hope National Medical Center, City of Hope, Massachusetts General Hospital, Colorado Blood Cancer Institute, Cleveland Clinic, Hackensack University Medical Center, Loyola University Medical Center, Loyola University Chicago, Loyola Medicine, University of Washington, Fred Hutch Cancer Center, The Barbara Ann Karmanos Cancer Institute, Sarah Cannon, Seagen (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596753223

FWCI: 5.268

Cites:

Cited by: 31

Related to: 10